title: Delayed onset panuveitis following intravitreal aflibercept injection.
abstract: Aflibercept has been listed on the Australian Pharmaceutical Benefit Scheme for the past year for neovascular age-related macular degeneration. Since that time there have not been any reports of delayed onset panuveitis. We present two cases of anterior and posterior uveitis that have occurred 4 weeks or more after first intravitreal injection of aflibercept. Both patients had received other vascular endothelial growth factor inhibitors prior to aflibercept administration without signs of inflammation and both cases had sterile endophthalmitis. On resolution of the inflammation the patients were recommenced on ranibizumab without further incident.
authors.affiliation: Department of Ophthalmology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
authors.forename: Jodi A
authors.initials: JA
authors.lastname: Glading
authors.affiliation: Department of Ophthalmology, Flinders Medical Centre, Bedford Park, South Australia, Australia Department of Ophthalmology, Flinders University, Bedford Park, South Australia, Australia.
authors.forename: Stewart R
authors.initials: SR
authors.lastname: Lake
authors.affiliation: Department of Ophthalmology, Flinders Medical Centre, Bedford Park, South Australia, Australia Department of Ophthalmology, Flinders University, Bedford Park, South Australia, Australia.
authors.forename: Jamie E
authors.initials: JE
authors.lastname: Craig
authors.affiliation: Department of Ophthalmology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
authors.forename: Devaraj
authors.initials: D
authors.lastname: Supramaniam
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D015864:Panuveitis / Q000139:chemically induced*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage / Q000009:adverse effects*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor